GP73在非酒精性脂肪性肝病中的临床价值  

Clinical value of GP73 in nonalcoholic fatty liver disease

作　　者：余健全 张栋武 罗家怡 冯凌思[1] YU Jian-quan;ZHANG Dong-wu;LUO Jia-yi(People's Hospital of Gaoming District,Foshan 528500,China)

机构地区：[1]佛山市高明区人民医院,528500

出　　处：《中国实用医药》2022年第25期48-52,共5页China Practical Medicine

摘　　要：目的 研究高尔基体蛋白73(GP73)在非酒精性脂肪性肝病(NAFLD)中的临床价值。方法 选取51例非酒精性单纯性肝脂肪肝患者(单纯性脂肪肝组)、83例非酒精性脂肪性肝炎(NASH)患者(NASH组)和70例健康体检者(健康对照组)作为研究对象,将NASH组患者分为早期NASH组(20例)、肝纤维化NASH组(37例)以及NASH肝硬化组(26例)。检测各组血清GP73水平及其他肝功能指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)、γ谷氨酰转肽酶(GGT)、总胆红素(TBil)、清蛋白(ALB)]。比较五组年龄及治疗前GP73水平, NASH肝硬化组、肝纤维化NASH组、早期NASH组患者治疗前后GP73水平;分析GP73与其他肝功指标(ALT、AST、TBIL、GGT、ALB)相关性及GP73鉴别显著性肝纤维化和肝硬化的临床价值。结果 五组年龄比较差异无统计学意义(P>0.05)。治疗前,健康对照组、单纯性脂肪肝组、NASH肝硬化组、肝纤维化NASH组、早期NASH组患者GP73分别为(45.35±22.65)、(49.67±28.48)、(160.33±39.91)、(102.31±44.26)、(75.54±26.79)ng/ml;治疗6个月后, NASH肝硬化组、肝纤维化NASH组、早期NASH组患者GP73分别为(124.63±42.56)、(83.44±26.90)、(58.27±21.75)ng/ml。单纯性脂肪肝组和健康对照组治疗前GP73水平比较差异无统计学意义(P>0.05);NASH肝硬化组、肝纤维化NASH组、早期NASH组治疗前GP73水平均高于单纯性脂肪肝组和健康对照组,差异具有统计学意义(P<0.05)。NASH肝硬化组治疗前GP73水平高于早期NASH组、肝纤维化NASH组,且肝纤维化NASH组GP73水平高于早期NASH组,差异具有统计学意义(P<0.05)。治疗后, NASH肝硬化组、肝纤维化NASH组、早期NASH组患者GP73水平均低于治疗前,差异具有统计学意义(P<0.05)。经Pearson相关性分析, GP73水平与ALT、AST、TBIL、GGT呈正相关(r=0.38、0.44、0.41、0.48, P<0.05),与ALB呈负相关(r=-0.53, P<0.05)。鉴别诊断显著性肝纤维化的曲线下面积(AUC)值、敏感性和特异性分别为0Objective To study the clinical value of golgi protein 73(GP73) in nonalcoholic fatty liver disease(NAFLD). Methods 51 patients with nonalcoholic simple fatty liver(simple fatty liver group),83 patients with nonalcoholic steatohepatitis(NASH)(NASH group) and 70 healthy subjects(healthy control group) were selected as the research subjects. The patients in NASH group were divided into early NASH group(20 cases), liver fibrosis NASH group(37 cases) and NASH cirrhosis group(26 cases). Serum GP73 levels and other liver function indexes [alanine aminotransferase(ALT), aspartate aminotransferase(AST), gamma glutamyl transpeptidase(GGT), total bilirubin(TBil), albumin(ALB)] in each group were detected. Comparison was made on the age and GP73 levels before treatment among the five groups, as well as the GP73 levels before and after treatment in NASH cirrhosis group, liver fibrosis NASH group and early NASH group. The correlation between GP73 and other liver function indexes(ALT, AST, TBIL, GGT, ALB), and the clinical value of GP73in distinguishing significant liver fibrosis and liver cirrhosis were analyzed. Results There was no statistically significant difference in age among the five groups(P>0.05). Before treatment, the GP73 in the healthy control group, simple fatty liver group, NASH cirrhosis group, liver fibrosis NASH group and early NASH group were(45.35±22.65),(49.67±28.48),(160.33±39.91),(102.31±44.26) and(75.54±26.79) ng/ml;after 6 months of treatment, the GP73 in NASH cirrhosis group, liver fibrosis NASH group, and early NASH group were(124.63±42.56),(83.44±26.90), and(58.27±21.75) ng/ml. There was no statistically significant difference in GP73 before treatment between the simple fatty liver group and the healthy control group(P>0.05). The GP73in NASH liver cirrhosis group, liver fibrosis NASH group and early NASH group before treatment were higher than those in simple fatty liver group and healthy control group, and the difference was statistically significant(P<0.05). Before treatment, the GP73 in

关 键 词：非酒精性脂肪肝性肝病 高尔基体蛋白73 多烯磷酯酰胆碱 

分 类 号：R575.5[医药卫生—消化系统]